Panorama from the oncolytic virotherapy summit.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Optimizing adjuvant treatment options for patients with glioblastoma.Frontiers in neurology · 2024
   Article
2. Oncolytic Virotherapy for the Treatment of Malignant Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
   Review
3. Glioblastoma antigen discovery--foundations for immunotherapy.Journal of neuro-oncology · 2015
   Review
4. Emerging treatment strategies for glioblastoma multiforme.EMBO molecular medicine · 2014
   Review
5. ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.Human gene therapy · 2014
   Article
6. Glioma virus therapies between bench and bedside.Neuro-oncology · 2014
   Review
7. Trial Watch:: Oncolytic viruses for cancer therapy.Oncoimmunology
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as